Oncopeptides was established solely to develop therapies for difficult-to-treat hematological diseases, and we are committed to bringing patients the treatments they need and the hope they deserve.
Visit our Virtual Booth to learn more about Oncopeptides.
Oncopeptides is focused on research and development of difficult-to-treat hematological diseases. A proprietary PDC platform includes compounds that rapidly and selectively delivers cytotoxic agents into cancer cells. The company has applied for a conditional marketing authorization of melflufen (melphalan flufenamide) in the EU in relapsed refractory multiple myeloma. The Headquarters is in Stockholm and the company is listed on Nasdaq Stockholm, Sweden. Please visit www.oncopeptides.com. Please email medinfo@oncopeptides.com for questions or inquiries. Please include your name, email address, organization, country, and question in the email.
https://events.jspargo.com/ASH21/CUSTOM/Oncopeptides%20Press%20Release%2010%20Dec%202021.pdf
Contact this Exhibitor